Therapeutics News and Research

RSS

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Azaya Therapeutics, Inc. has announced that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Azaya's lead cancer therapy, ATI - 1123.

10 Mar 2009

Challenge of a cure for HIV infection

A group including leading academic and industry scientists has issued a challenge to researchers in the field of HIV/AIDS: find a way to effectively purge latent HIV infection and eliminate the need for chronic, suppressive therapy to control this disease.

5 Mar 2009

Three biomarkers found for Chikungunya fever

Three specific biomarkers provide an accurate indication of the severity of Chikungunya fever (CHIKF), which is emerging as a threat in South-East Asia, the Pacific and Europe, according to research conducted in Singapore.

4 Mar 2009

Type 1 diabetes patients sought for UT Southwestern clinical drug trial

UT Southwestern Medical Center researchers are recruiting individuals newly diagnosed with type 1 diabetes for a clinical trial to gauge the effectiveness of adding an investigational stem cell product to standard insulin therapy.

3 Mar 2009

Instant immunity through chemically programmable vaccination and covalent self-assembly

The experiments, thus far performed only in mice, appear to overcome a major drawback of vaccinations - the lag time of days, or even weeks, that it normally takes for immunity to build against a pathogen.

2 Mar 2009

Experimental drug fampridine improves mobility for some MS patients

In MS, the body's immune system attacks myelin, a fatty tissue that wraps and insultates nerve fibers, disrupting the transmission of signals in the central nervous system.

1 Mar 2009

New software aids discovery of new genetic markers for diseases

Modern genotyping technologies offer new opportunities to explore how genes influence health and disease, but also present the challenge of analyzing huge amounts of genetic and clinical data.

26 Feb 2009

Human stem cells provide a new model for Lou Gehrig's disease

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a devastating condition in which motor neuron degeneration causes progressive loss of movement and muscle tone, leading to death.

23 Feb 2009

Gold nanoparticles improve gene regulation

Investigators at Northwestern University have found that packing small interfering RNA (siRNA) molecules onto the surface of a gold nanoparticle can protect siRNAs from degradation and increase their ability to regulate genes involved in cancer. As a result of this discovery, cancer researchers have at their disposal a relatively straightforward method of delivering these potent gene-regulating agents into targeted cells.

23 Feb 2009

Microfluidic device mimics tumor microenvironment, helps drug discovery

One of the challenges that cancer researchers face in designing new antitumor agents is that of predicting how drug molecules will behave in the complex microenvironment that surrounds a tumor. In particular, tumors create all sorts of chemical and physical barriers that limit how much drug is able to enter a tumor, let alone reach cells deep within a tumor.

23 Feb 2009

Presence of a biomarker in regional lymph nodes predicts disease recurrence in colorectal cancer

Findings published in the Journal of the American Medical Association by researchers at Thomas Jefferson University show that the presence of a biomarker in regional lymph nodes is an independent predictor of disease recurrence in patients with colorectal cancer.

18 Feb 2009

Cellular changes in the sleeping brain promote the formation of memories

If you ever argued with your mother when she told you to get some sleep after studying for an exam instead of pulling an all-nighter, you owe her an apology, because it turns out she's right.

15 Feb 2009

Discovery of potential treatment for Rett syndrome

A molecule that promotes brain development could serve as a possible treatment for Rett syndrome, the most common form of autism in girls, according to researchers at MIT's Picower Institute for Learning and Memory and the Whitehead Institute for Biomedical Research.

9 Feb 2009

Researchers 'tighten' body's protective coating

A net with large holes won't catch small fish. Likewise, the microscopic fibers in the protective mucus coatings of the eyes, lungs, stomach or reproductive system naturally bundle together and allow the tiniest disease-causing bugs, allergens or pollutants to slip by.

8 Feb 2009

Researchers find pathway and enzyme unique to tularemia organism

Researchers are closer to developing therapies to combat the deadly tularemia infection, according to a study published this week in the Proceedings of the National Academy of Sciences' online Early Edition.

3 Feb 2009

New findings raise questions about process used to identify experimental drug

A study by National Institutes of Health (NIH) researchers has revealed surprising new insights into the process used to initially identify an experimental drug now being tested in people with cystic fibrosis and muscular dystrophy.

3 Feb 2009

Insulin may slow or prevent damage caused by toxic proteins in Alzheimer's disease

A Northwestern University-led research team reports that insulin, by shielding memory-forming synapses from harm, may slow or prevent the damage and memory loss caused by toxic proteins in Alzheimer's disease.

2 Feb 2009

New technology analyzes breast cancer tumours to determine best treatment option

In a study published by Nature Biotechnology online on February 1, 2009, Mount Sinai Hospital researchers have unveiled a new technology tool that analyzes breast cancer tumours to determine a patient's best treatment options.

2 Feb 2009

New understanding of Ebola virus and tetherin protein

Researchers at the University of Pennsylvania School of Medicine have likely found one reason why the Ebola virus is such a powerful, deadly, and effective virus.

29 Jan 2009

Stromedix awarded U.S. patent for antibody-based therapeutics

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that the U.S. Patent Office has granted patent number US 7,465,449, which broadly covers monoclonal antibodies to integrin ávâ6, including compositions related to its lead product, STX-100.

23 Jan 2009